Clearmind Medicine (XCNQ:CMND) EV-to-EBITDA : 0.04 (As of Apr. 27, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Clearmind Medicine EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Clearmind Medicine's enterprise value is C$-0.30 Mil. Clearmind Medicine's EBITDA for the trailing twelve months (TTM) ended in Oct. 2023 was C$-6.88 Mil. Therefore, Clearmind Medicine's EV-to-EBITDA for today is 0.04.

The historical rank and industry rank for Clearmind Medicine's EV-to-EBITDA or its related term are showing as below:

XCNQ:CMND' s EV-to-EBITDA Range Over the Past 10 Years
Min: -80.12 Med: 0 Max: 4.87
Current: 0.04

During the past 7 years, the highest EV-to-EBITDA of Clearmind Medicine was 4.87. The lowest was -80.12. And the median was 0.00.

XCNQ:CMND's EV-to-EBITDA is ranked better than
95.76% of 472 companies
in the Biotechnology industry
Industry Median: 9.1 vs XCNQ:CMND: 0.04

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-27), Clearmind Medicine's stock price is C$1.60. Clearmind Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 was C$-57.701. Therefore, Clearmind Medicine's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Clearmind Medicine EV-to-EBITDA Historical Data

The historical data trend for Clearmind Medicine's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine EV-to-EBITDA Chart

Clearmind Medicine Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

EV-to-EBITDA

Get a 7-Day Free Trial

-8.45

-7.81

-8.33

-1.73

0.45

Clearmind Medicine Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23
EV-to-EBITDA	Get a 7-Day Free Trial															-1.73	-1.16	0.01	-0.05	0.45

Competitive Comparison of Clearmind Medicine's EV-to-EBITDA

For the Biotechnology subindustry, Clearmind Medicine's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clearmind Medicine's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearmind Medicine's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Clearmind Medicine's EV-to-EBITDA falls into.

Clearmind Medicine EV-to-EBITDA Calculation

Clearmind Medicine's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	-0.304	/	-6.884
	=	0.04

Clearmind Medicine's current Enterprise Value is C$-0.30 Mil.
Clearmind Medicine's EBITDA for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-6.88 Mil.

Clearmind Medicine (XCNQ:CMND) EV-to-EBITDA Explanation

Clearmind Medicine's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	1.60	/	-57.701
	=	At Loss

Clearmind Medicine's share price for today is C$1.60.
Clearmind Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-57.701.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Clearmind Medicine EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearmind Medicine (XCNQ:CMND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (XCNQ:CMND) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

CMND:USA CWY0:Germany

Address

101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5

Website

https://www.clearmindmedicine.com

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.